Core Insights - The stock of Meihao Medical (301363) closed at 20.95 yuan on November 25, 2025, with a slight increase of 0.58% and a trading volume of 34,400 hands, resulting in a transaction amount of 72.4574 million yuan [1] Fund Flow Analysis - On November 25, 2025, the net outflow of main funds was 2.3287 million yuan, accounting for 3.21% of the total transaction amount, while retail investors saw a net inflow of 465,400 yuan, representing 0.64% of the total [1][2] - Over the past five days, the stock experienced fluctuating fund flows, with significant net outflows from main funds on November 24 and November 21, totaling 4.2916 million yuan and 5.3390 million yuan respectively [2] Company Performance Metrics - Meihao Medical's total market capitalization is 11.918 billion yuan, with a net asset value of 3.702 billion yuan and a net profit of 208 million yuan [3] - The company's price-to-earnings ratio (P/E) stands at 42.93, while the price-to-book ratio (P/B) is 3.22, indicating a relatively high valuation compared to the industry averages [3] - The gross margin is reported at 39.34%, which is lower than the industry average of 51.22%, while the net profit margin is 17.43%, significantly higher than the industry average of 9.57% [3] Recent Institutional Ratings - In the last 90 days, 14 institutions have rated the stock, with 12 buy ratings and 2 hold ratings, indicating a positive outlook from analysts [4] - The average target price set by institutions over the past 90 days is 25.2 yuan, suggesting potential upside from the current trading price [4]
股票行情快报：美好医疗（301363）11月25日主力资金净卖出232.87万元